Infection à Chlamydia trachomatis

This bacterial organism colonizes multiple mucosal surfaces, including the urethra, vaginal canal, cervix, rectum, and pharyngeal tissue ^[1]. Ocular manifestations originate from recurrent conjunctival colonization typically initiated during early childhood ^[2]. Microbiological investigations indicate potential interactions with resident cervical and vaginal microbial communities, though meta-analytical data on diversity shifts remain inconsistent ^[3].

The majority of infected individuals exhibit no overt symptoms ^[1]. Genital involvement in females may progress to upper tract inflammation, elevating susceptibility to ectopic gestation, tubal factor infertility, and persistent pelvic discomfort ^[1]. Male presentations frequently encompass epididymal inflammation and rectal mucosal disease ^[1]. Ocular disease evolves from acute conjunctival inflammation to progressive scarring and eyelash malposition ^[2].

Global health monitoring consistently ranks this pathogen as the most frequently reported bacterial sexually transmitted infection across varied demographic groups ^[1]. Sustained diagnostic reporting reflects its continuous circulation within general populations, highlighting its enduring prevalence ^[1].

Primary dissemination occurs through direct sexual contact involving genital, anal, or oral mucosal exchange ^[1]. Ocular strain propagation is closely tied to environmental conditions and hygiene access within densely populated or resource-limited settlements ^[2]. Variations in healthcare delivery models and institutional competencies further shape how transmission networks are identified and interrupted ^[4].

Public health frameworks emphasize clinical management protocols and targeted screening initiatives to curb community spread ^[1]. Eradication campaigns for ocular disease utilize a multifaceted approach combining surgical correction, population-wide antimicrobial therapy, facial hygiene promotion, and infrastructure upgrades ^[2]. Operational challenges regarding diagnostic assay availability and laboratory service distribution require coordinated mitigation to sustain preventive efforts ^[4].

1. 1 Hocking JS et al. Update on the Epidemiology, Screening, and Management of Chlamydia trachomatis Infection. Infect Dis Clin North Am. 2023 Jun. PMID: 37005162. doi: 10.1016/j.idc.2023.02.007. PubMed: https://pubmed.ncbi.nlm.nih.gov/37005162/
2. 2 Habtamu E et al. Trachoma. Lancet. 2025 May 24. PMID: 40412861. doi: 10.1016/S0140-6736(25)00551-3. PubMed: https://pubmed.ncbi.nlm.nih.gov/40412861/
3. 3 Di Pietro M et al. Cervicovaginal Microbiota Composition in Chlamydia trachomatis Infection: A Systematic Review and Meta-Analysis. Int J Mol Sci. 2022 Aug 23. PMID: 36076948. doi: 10.3390/ijms23179554. PubMed: https://pubmed.ncbi.nlm.nih.gov/36076948/
4. 4 Del Romero J et al. Sexually transmitted infections in Spain: Current status. Rev Esp Quimioter. 2023 Oct. PMID: 37335757. doi: 10.37201/req/038.2023. PubMed: https://pubmed.ncbi.nlm.nih.gov/37335757/
5. 5 Passos LG et al. The Correlation between Chlamydia Trachomatis and Female Infertility: A Systematic Review. Rev Bras Ginecol Obstet. 2022 Jun. PMID: 35576969. doi: 10.1055/s-0042-1748023. PubMed: https://pubmed.ncbi.nlm.nih.gov/35576969/